By Josh Beckerman
Precigen received Food and Drug Administration approval of its lead product candidate, a drug for treatment of adults with recurrent respiratory papillomatosis.
The drug, which had been known as PRGN-2012, is now called Papzimeos.
Recurrent respiratory papillomatosis, caused by persistent human papillomavirus infection, leads to the growth of benign tumors in the respiratory tract, generally in the larynx.
In February, the FDA granted priority review, with a Prescription Drug User Fee Act target action date of Aug. 27.
Write to Josh Beckerman at josh.beckerman@wsj.com
(END) Dow Jones Newswires
August 14, 2025 19:21 ET (23:21 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。